^
Association details:
Biomarker:No biomarker
Cancer:Mantle Cell Lymphoma
Drug:Imbruvica (ibrutinib) (BTK inhibitor) +
Rituxan (rituximab) (CD20 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Mantle Cell Lymphoma: SECOND-LINE AND SUBSEQUENT THERAPY...Preferred regimens...Ibrutinib+/-rituximab Mantle Cell Lymphoma….MAINTENANCE AFTER HDT/ASCR OR AGGRESSIVE INDUCTION THERAPY….Covalent BTKi x 2 years (category 2A for ibrutinib; category 2B for acalabrutinib or zanubrutinib) + rituximab every 8 weeks x 3 y (category 1 for rituximab following HDT/ASCR)